An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials

Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low‐risk clinical trials: A report from the Children's Oncology Group

(2021) Jamie M. Aye et al.   PEDIATRIC BLOOD & CANCER

Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience

(2021) Christophe Bergeron et al.   EUROPEAN JOURNAL OF CANCER

Relapsed Rhabdomyosarcoma

(2021) Christine M. Heske et al.   Journal of Clinical Medicine

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

(2021) Holly L. Pacenta et al.   Journal of Clinical Medicine

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium

(2021) Jack F. Shern et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

(2020) Kara L Davis et al.   LANCET ONCOLOGY

Survival outcomes of patients with localized FOXO1 fusion‐positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

(2020) Christine M. Heske et al.   CANCER

Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe

(2020) Erin R. Rudzinski et al.   PEDIATRIC BLOOD & CANCER

Rhabdomyosarcoma

(2019) Stephen X. Skapek et al.   Nature Reviews Disease Primers

Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

(2019) Dana L. Casey et al.   CANCER

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group

(2019) Leo Mascarenhas et al.   JOURNAL OF CLINICAL ONCOLOGY

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

(2019) Gianni Bisogno et al.   LANCET ONCOLOGY

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

(2019) Emily Hibbitts et al.   Cancer Medicine

Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma

(2019) Dana L Casey et al.   CLINICAL CANCER RESEARCH

Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

(2018) Soledad Gallego et al.   CANCER

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’

(2018) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

(2018) Douglas S. Hawkins et al.   JOURNAL OF CLINICAL ONCOLOGY

MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification

(2018) Narasimhan P. Agaram et al.   MODERN PATHOLOGY

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

(2018) Suman Malempati et al.   CANCER

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

(2017) Erin R. Rudzinski et al.   PEDIATRIC BLOOD & CANCER

45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy

(2017) Ralph P. Ermoian et al.   PEDIATRIC BLOOD & CANCER

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2016) Brenda J. Weigel et al.   JOURNAL OF CLINICAL ONCOLOGY

MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes

(2016) Bharat Rekhi et al.   MODERN PATHOLOGY

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group

(2016) Michael A. Arnold et al.   PEDIATRIC BLOOD & CANCER

SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma

(2015) Scott M. Schuetze et al.   CANCER

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

(2015) AeRang Kim et al.   PEDIATRIC BLOOD & CANCER

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

(2014) Alberto S. Pappo et al.   CANCER

RecurrentMYOD1mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis

(2014) Narasimhan P. Agaram et al.   GENES CHROMOSOMES & CANCER

Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

(2014) David O. Walterhouse et al.   JOURNAL OF CLINICAL ONCOLOGY

MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma

(2014) E. K. Slotkin et al.   MOLECULAR CANCER THERAPEUTICS

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations

(2014) Shinji Kohsaka et al.   NATURE GENETICS

Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors

(2014) J. F. Shern et al.   Cancer Discovery

Classification of Rhabdomyosarcoma and Its Molecular Basis

(2013) David M. Parham et al.   ADVANCES IN ANATOMIC PATHOLOGY

Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model

(2013) Samer Z. Kaylani et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development

(2013) X. Le et al.   DEVELOPMENT

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group

(2013) Brenda Weigel et al.   PEDIATRIC BLOOD & CANCER

PAX-FOXO1fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

(2013) Stephen X. Skapek et al.   PEDIATRIC BLOOD & CANCER

Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE)

(2012) Véronique Minard-Colin et al.   EUROPEAN JOURNAL OF CANCER

Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: A report from the Children's Oncology Group

(2012) Fenghai Duan et al.   GENES CHROMOSOMES & CANCER

PAX3/FOXO1Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification

(2012) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study

(2012) Anne B. Warwick et al.   PEDIATRIC BLOOD & CANCER

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

(2012) Douglas S. Hawkins et al.   PEDIATRIC BLOOD & CANCER

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

(2011) Sylvain Baruchel et al.   EUROPEAN JOURNAL OF CANCER

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

(2011) R. Beverly Raney et al.   JOURNAL OF CLINICAL ONCOLOGY

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

(2010) P. J. Houghton et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study

(2010) Orren Beaty et al.   PEDIATRIC BLOOD & CANCER

Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group

(2009) Frederic G. Barr et al.   GENES CHROMOSOMES & CANCER

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

(2009) Carola A.S. Arndt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group study

(2009) John F. Kuttesch et al.   PEDIATRIC BLOOD & CANCER

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER